These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 8830165)

  • 21. Drug Insight: interferon treatment in multiple sclerosis.
    Marrie RA; Rudick RA
    Nat Clin Pract Neurol; 2006 Jan; 2(1):34-44. PubMed ID: 16932519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis: immune mechanism and update on current therapies.
    Bansil S; Cook SD; Rohowsky-Kochan C
    Ann Neurol; 1995 May; 37 Suppl 1():S87-101. PubMed ID: 8968220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis. II. A critical assessment of immunotherapy.
    Durelli L; Bergamini L
    Riv Neurol; 1989; 59(5):191-201. PubMed ID: 2483962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis: clinical presentation, diagnosis and treatment.
    Brod SA; Lindsey JW; Wolinsky JS
    Am Fam Physician; 1996 Sep; 54(4):1301-6, 1309-11. PubMed ID: 8816574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy in multiple sclerosis.
    Conway D; Cohen JA
    Lancet Neurol; 2010 Mar; 9(3):299-308. PubMed ID: 20170843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863).
    Gladstone DE; Peyster R; Baron E; Friedman-Urevich S; Sibony P; Melville P; Gottesman M
    Am J Ther; 2011 Jan; 18(1):23-30. PubMed ID: 19770795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status and future prospective of immunointervention in multiple sclerosis.
    Cavaletti G
    Curr Med Chem; 2006; 13(19):2329-43. PubMed ID: 16918358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute inflammatory demyelinating optic neuritis: evidence-based visual and neurological considerations.
    Abou Zeid N; Bhatti MT
    Neurologist; 2008 Jul; 14(4):207-23. PubMed ID: 18617847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Humle Jorgensen S; Sorensen PS
    J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic potential of interferon beta-1b and related drugs in multiple sclerosis: comparative meta-analysis].
    Cendrowski W
    Neurol Neurochir Pol; 2001; 35(4 Suppl):125-38. PubMed ID: 11873611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
    Orthmann-Murphy JL; Calabresi PA
    Clin Pharmacol Ther; 2017 Jan; 101(1):52-64. PubMed ID: 27804128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Other therapy options and future strategies for treating patients with multiple sclerosis.
    Rizvi SA; Bashir K
    Neurology; 2004 Dec; 63(12 Suppl 6):S47-54. PubMed ID: 15623671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M; Ghezzi A; Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.